Search

Displaying results 4561 - 4570 of 5449 in total
  1. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    It is injected once every four weeks via intravenous infusion. Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype. … It is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Reslizumab is marketed as Cinqaero in Europe.

  2. Drug

    Galidesivir

    go.drugbank.com/drugs/DB11676
    Investigational

    [L12042] Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19. … [L12084] _In vitro_, it displayed broad-spectrum antiviral activity against various negative- and positive-sense RNA viruses,[A191622] including coronaviruses, filoviruses, and arenaviruses.

  3. Drug

    TMC-310911

    go.drugbank.com/drugs/DB15623
    Investigational

    [L12045] It is being investigated for use in HIV-1 infections. … TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, making it a potentially desirable therapy for

  4. Drug

    Tezosentan

    go.drugbank.com/drugs/DB06558
    Investigational

    Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.

  5. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.

  6. Drug

    Talacotuzumab

    go.drugbank.com/drugs/DB14796
    Investigational

    It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).

  7. Drug

    SOBI-003

    go.drugbank.com/drugs/DB15451
    Investigational

    It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).

  8. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and inclusion body myositis.[L46742, L46747, L46752]

  9. Drug

    SRP-9005

    go.drugbank.com/drugs/DB17958
    Investigational

    Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.[A260142]

  10. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been disc...